CTOs on the Move

Avinger

www.avinger.com

 
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.avinger.com
  • 400 Chesapeake Dr
    Redwood City, CA USA 94063
  • Phone: 650.363.2400

Executives

Name Title Contact Details

Funding

Avinger raised $18M on 02/14/2018
Avinger raised $11.5M on 11/07/2018

Similar Companies

Claret Medical

Claret Medical has been the leader in the field of cerebral protection since 2011, with approximately 97% market share in Europe, and is the first in the category to be commercially available in the U.S.

Tri-Medical

Tri-Medical is a Lake Oswego, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radlink

Radlink, Inc. is a Redondo Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.

Cayenne Medical

Cayenne Medical is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.